The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery
Practical Fragments: Second fragment-based drug approved
Venetoclax (ABT-199) | BCL-2 Inhibitor | MedChemExpress
Venetoclax (ABT-199): a Selective Inhibitor of B-Cell Lymphoma-2 | Personalized Medicine in Oncology
Venetoclax | ABT-199 | GDC-0199 | CAS#1257044-40-8 | BCL-2 Inhibitor | MedKoo
Venetoclax - Wikipedia
Imaging Cellular Distribution of Bcl Inhibitors Using Small Molecule Drug Conjugates
![PDF] ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fdf95a15ef1cbf1ab603cd15531b69fef7da162f/7-Figure5-1.png "PDF] ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. | Semantic Scholar")
PDF] ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. | Semantic Scholar
Updated Results of a Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia | Research To Practice
.gif "ABT-199 (Venetoclax) - Chemietek")
ABT-199 (Venetoclax) - Chemietek
Functional evaluation of Bcl2 and BAX mutations. (A) ABT-199 was unable... | Download Scientific Diagram
Model for ABT-199-resistance and PI3K-mTOR-mediated targeting of... | Download Scientific Diagram
Clinical trials of venetoclax/ABT-199 in combination regimens | Download Table
An Unexpected Halt in Multiple Myeloma for Venetoclax | Science | AAAS
Identification of tivantinib and ABT-199 as a synergistic drug... | Download Scientific Diagram
ABT‐199 (Venetoclax), a BH3‐mimetic Bcl‐2 inhibitor, does not cause Ca2+‐signalling dysregulation or toxicity in pancreatic acinar cells - Jakubowska - 2019 - British Journal of Pharmacology - Wiley Online Library
ABT-199 activates the intrinsic mitochondrial apoptosis pathway in... | Download Scientific Diagram
Navitoclax - an overview | ScienceDirect Topics
The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA. - Abstract - Europe PMC
Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells | Signal Transduction and Targeted Therapy
Frontiers | The Basic Research of the Combinatorial Therapy of ABT-199 and Homoharringtonine on Acute Myeloid Leukemia
Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors | Haematologica
Attacking cancer's Achilles heel: antagonism of anti‐apoptotic BCL‐2 family members - Opferman - 2016 - The FEBS Journal - Wiley Online Library
